Sobi's $75 Million Upfront Buys Innate Pharma Time Until 2028

Innate Pharma S.A. (NASDAQ:IPHA) closed its lacutamab partnership with Sobi on September 16, triggering a $75 million upfront payment that management says funds the company through the end of the first quarter of 2028.

The deal came a day before the company reported a €19.6 million net loss for the first half of the year, according to results published September 17. The funding runway also includes a completed equity financing that raised €30 million in gross proceeds.

The centerpiece of the arrangement is TELLOMAK-3, the confirmatory Phase 3 trial for lacutamab. Innate Pharma will conduct the trial itself. Sobi receives exclusive global commercialization rights upon potential accelerated approval, and can subsequently assume full global development rights following positive Phase 3 results.

That structure matters for a company of Innate Pharma's size. It could reduce the need to build a commercial organization independently, while retained milestone and royalty rights keep Innate invested in the drug's success.

The economics are substantial. Innate Pharma is eligible for up to $40 million in near-term development milestones, plus up to $465 million tied to the development-rights option and regulatory and commercial milestones. Tiered double-digit royalties would apply to net sales. Those payments could become future funding as the program advances.

The cost base is also moving in the right direction. First-half operating expenses fell to €24.7 million from €30.3 million a year earlier. Lower spending gives the new financing a stronger starting point, though future trial activity will determine the spending trajectory.

Beyond lacutamab, the pipeline offers nearer-term readouts. Innate Pharma expects initial Phase 1 data for IPH4502, its Nectin-4 antibody-drug conjugate, in November. The partnered monalizumab program's PACIFIC-9 Phase 3 results are expected in the second half of 2026.

The clinical calendar is the main constraint. First-patient enrollment in TELLOMAK-3 is expected only in the first quarter of 2027. That timing would put the projected cash horizon approximately 12 to 15 months beyond the first-patient milestone. Management's forecast does not establish that funding covers the trial through completion or a commercial launch.

Innate Pharma retains responsibility for conducting the trial. Site activation, recruitment, treatment and follow-up must all proceed effectively before the partnership can deliver its larger potential rewards. A commercial partner does not eliminate clinical or regulatory risk.

For investors, the Sobi deal buys time and optionality: $75 million upfront, up to $505 million in milestones and double-digit royalties against a fixed obligation to deliver a Phase 3 trial. Whether that math works depends on execution in the clinic starting in early 2027.